BDX · Full Picture
BECTON DICKINSON & CO — the full picture
Earnings window · 2026-07-16 to 2026-08-09 · anchored on the 10-Q report
One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.
What to look at first
- Segment Revenue Performance · Revenue growth & mixPriority 79+23.0% revenue (realized); 3 sources (news, press_release, sec_filing); structured_verifiedNine months ended June 30, 2026 net income: $449 million versus $1,185 million prior year (down 62.1%).
- Headcount / Restructuring · Restructuring & impairmentPriority 76-9.0% operating_income (realized); 2 sources (press_release, sec_filing); structured_verifiedThe nine-month period of 2026 included non-cash asset impairment charges of $450 million recorded upon BD's commitment to exit certain operational activities and projects.
- Liquidity and Debt Position · Debt, leverage & refinancingPriority 76+8.0% cash (realized); 2 sources (press_release, sec_filing); structured_verifiedIn connection with the Transaction, BD received a $4 billion cash distribution which was used to fund second quarter share repurchases and debt repayments.
- Acquisition / Partnership / Divestiture · M&A and divestituresPriority 713 sources (news, press_release, sec_filing); 2 forward row(s); quote_verifiedOn February 9, 2026, BD completed the spin-off of its former Biosciences and Diagnostic Solutions business and the combination of the business with Waters Corporation in a Reverse Morris Trust transaction.
- Restructuring and Impairments · Restructuring & impairmentPriority 66-9.1% operating_income (realized); quote_verifiedNine months ended June 30, 2026 integration, restructuring and transaction expense: $729 million versus $277 million prior year (162.9% increase).
- Capital Return Program · Buybacks & dividendsPriority 61-2.9% cash (realized); 2 sources (news, sec_filing); structured_verifiedRepurchases of common stock in the nine months ended June 30, 2026 were $(2,250) million compared with $(750) million in the prior-year period.
- Operating Expense Trends · Operating expenses (SG&A)Priority 60+8.0% operating_income (realized); quote_verifiedSpecified items presented for the three months ended June 30, 2026 totaled $1,986 million and $2,015 million for the three months ended June 30, 2025.
- Free Cash Flow and Liquidity · UnclassifiedPriority 592 sources (news, press_release); quote_verifiedFree cash flow increased 44.6% year-to-date to $1.7 billion.
- Operating Margin Drivers · Operating income & profitabilityPriority 59-9.4% operating_income (realized); 2 sources (news, press_release); quote_verifiedThird quarter fiscal 2026 operating income: $663 million, down 10.3% versus $739 million in the prior year period.
- Geographic Market Commentary · Geographic mixPriority 57+5.2% revenue (realized); 2 sources (press_release, sec_filing); quote_verifiedU.S. revenues for the three months ended June 30, 2026 were $3,081 million, up 6.9% (FXN change 6.9%, estimated FX impact —).
- Spin-off and Combination · M&A and divestituresPriority 53-4.0% net_income (realized); quote_verifiedLoss from discontinued operations, net of tax, for the three months ended June 30, 2026: $(74) million versus income of $123 million prior year (change of (159.8)%).
- Guidance and Outlook · Guidance & outlookPriority 522 sources (news, press_release); 2 forward row(s); quote_verifiedFollowing Q3 results, the company raised its full-year fiscal 2026 adjusted diluted EPS guidance midpoint to $12.67.
Threads by pillar
Revenue & Demand Priority 87 · 6 threads
- Segment Revenue PerformancePriority 79 · News, Release, Filing
- Geographic Market CommentaryPriority 57 · Release, Filing
- Product Launch and TransitionPriority 37 · Filing
- Products and TechnologyPriority 34 · Release
- Market Demand TrendsPriority 29 · Release
- Customer DynamicsPriority 23 · Release
Costs & Margins Priority 89 · 6 threads
- Headcount / RestructuringPriority 76 · Release, Filing
- Restructuring and ImpairmentsPriority 66 · Release
- Operating Expense TrendsPriority 60 · Filing
- Operating Margin DriversPriority 59 · News, Release
- Gross Margin DriversPriority 46 · News, Filing
- Supply Chain ConstraintsPriority 31 · Filing
Capital & Balance Sheet Priority 86 · 4 threads
- Liquidity and Debt PositionPriority 76 · Release, Filing
- Capital Return ProgramPriority 61 · News, Filing
- Income Tax Rate ChangesPriority 41 · Filing
- Capital ExpendituresPriority 30 · Filing
Strategy & Portfolio Priority 75 · 3 threads
- Acquisition / Partnership / DivestiturePriority 71 · News, Release, Filing
- Spin-off and CombinationPriority 53 · Release
- Licensing / Collaboration DealsPriority 33 · News
Legal, Regulatory & Policy Priority 64 · 5 threads
- FDA El Paso Warning LetterPriority 43 · Filing
- Regulatory Approval MilestonesPriority 43 · Filing
- Regulatory RiskPriority 34 · News
- Trade Policy and TariffsPriority 50 · News, Filing
- Litigation and Legal RiskPriority 29 · Release
Guidance & Outlook Priority 56 · 2 threads
- Guidance and OutlookPriority 52 · News, Release
- Revenue Guidance UpdatePriority 49 · Release
Macro & Market Conditions Priority 47 · 3 threads
- FX / Currency HeadwindsPriority 37 · Release
- Competition and Market SharePriority 26 · Filing
- Middle East Conflict ImpactPriority 22 · Filing
Unclassified Priority 69 · 3 threads
- Free Cash Flow and LiquidityPriority 59 · News, Release
- Ethylene Oxide CostsPriority 41 · Filing
- China Healthcare Cost ControlsPriority 30 · Filing
Expected impact by metric
| metric | forward net | forward gross | realized |
|---|---|---|---|
| revenue | +0.8% | +0.8% | +28.2% |
| liability | — | — | +4.7% |
| operating_income | — | — | -20.6% |
| cash | — | — | +5.1% |
| assets | — | — | -0.9% |
| margin | — | — | +1.6% |
| net_income | — | — | -18.7% |